PEN Inc. Announces 1-for-180 Reverse Stock Split

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PEN Inc. Announces 1-for-180 Reverse Stock Split

MIAMI, FL --(Marketwired - January 26, 2016) -  PEN Inc. ( OTCQB : PENC ) ( OTCQB : PENCD ) ("PEN" or "the Company"), a global leader in developing, commercializing and marketing enhanced performance products enabled by nanotechnology, today announced a 1-for-180 reverse split of its issued and outstanding shares of common stock.

Trading will begin on a post-split basis at the opening of the OTCQB marketplace on January 26, 2016. The Company's common stock will trade under the symbol "PENCD," with a "D" added for 20 trading days to signify that the reverse stock split has occurred. The new CUSIP number for the common stock following the reverse stock split is 706582 202. 

The reverse stock split will reduce the total number of shares outstanding from approximately 543 million to approximately 3 million. Concurrent with the reverse stock split, the authorized shares of common stock will be reduced from 1.8 billion to 10 million. No fractional shares will be issued. If, as a result of the reverse stock split, a registered or beneficial stockholder would otherwise become entitled to receive a fractional share of common stock, the Company will round up to one whole share of common stock.

"We believe effecting a reverse split of our common stock serves the long-term interest of our shareholders, allowing us to attract interest from a broader range of investors and potential business partners. It also is an initial step to trading on the OTCQX," said Dr. Scott Rickert, PEN's Chairman and CEO.

Additional information about the reverse stock split can be found in the Company's definitive information statement filed with the Securities and Exchange Commission on December 29, 2015, a copy of which is available at  www.sec.gov  or at  www.penc.us under Investor Relations & News section of the website.

About PEN Inc. PEN Inc. ( OTCQB : PENC ) is a global leader in developing, commercializing, and marketing enhanced performance products enabled by nanotechnology that solve everyday problems for customers in the optical, transportation, military, sports, and safety industries. Through its wholly-owned subsidiary Nanofilm Ltd., the Company develops, manufactures and sells products based on nanotechnology including its Ultra Clarity® brand eyeglass cleaner and Defog It™ brand defogging products. The Company also sells its environmentally friendly HALO™ brand surface protector, fortifier, and cleaner through its wholly-owned subsidiary, PEN Technology, LLC. The Company's Applied Nanotech, Inc. subsidiary in Austin, Texas functions as the Design Center conducting research and development services for government and private customers and new product development for PEN focusing on innovative and advanced product solutions in the areas of safety, health, and sustainability. For more information about PEN, visit  www.penc.us .

Safe Harbor Statement This press release contains forward-looking statements that involve risks and uncertainties concerning our business, products, and financial results. Actual results may differ materially from the results predicted. More information about potential risk factors that could affect our business, products, and financial results are included in our annual report on Form 10-K for the fiscal year ended December 31, 2014, and in reports subsequently filed by us with the Securities and Exchange Commission ("SEC"). All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval System (EDGAR) at  www.sec.gov  or from our website listed above. We hereby disclaim any obligation to publicly update the information provided above, including forward-looking statements, to reflect subsequent events or circumstances.

Contact Information: PEN Inc. Elaine Ketchmere Email contact (844) 273-6462

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 29

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 17

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 16

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 22

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 23

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Alterity Therapeutics Showcases Innovation at Healthcare Event

Updated Category News Views 142

Alterity Therapeutics to Present at a Virtual Healthcare Conference Alterity Therapeutics, a biotechnology firm dedicated to developing treatments for neurodegenerative diseases, has recently announced its participation in an upcoming healthcare virtual conference. The event will shine a spotlight on influential healthcare companies and their innovative approaches to...

Continue Reading
Important Update for Toronto-Dominion Bank Investors on Lawsuit

Updated Category News Views 58

Update for Investors in Toronto-Dominion Bank Kahn Swick & Foti, LLC, led by the experienced former Louisiana Attorney General Charles C. Foti, Jr., is reminding investors that significant changes are arriving for shareholders of Toronto-Dominion Bank (NYSE: TD). As the legal landscape evolves, those who experienced losses may want to take immediate action regarding their...

Continue Reading
GCC's Quarterly Performance Analysis: Key Insights Revealed

Updated Category News Views 221

GCC Reports Significant First Quarter Financials GCC, S.A.B. de C.V. (BMV: GCC*), recognized as a premier supplier and producer of cement, concrete, and aggregates, has shared its financial results for the first quarter. Despite facing various challenges, GCC's performance metrics reveal a resilience that is noteworthy. Q1 2025 Highlights In the first quarter of 2025, GCC...

Continue Reading
Indonesia's IDX Composite Index Declines Amid Market Pressures

Updated Category News Views 116

Overview of Recent Market Movements in Indonesia Indonesia's stock market experienced a downturn at the close of trading, influenced by various sectors showing significant losses. The IDX Composite Index reflected a decrease of 0.98%, marking a notable dip to a one-month low. This downturn is primarily attributed to declines in several key sectors, including...

Continue Reading
Blink Charging Achieves Advanced Certification for EV Chargers

Updated Category News Views 130

Blink Charging Receives Prestigious OCPP 2.0.1 Certification Blink stands out as one of just five EV charging companies in the U.S. to earn this coveted certification. Bowie, Md. – Blink Charging Co. (NASDAQ: BLNK), a prominent name in electric vehicle (EV) charging equipment and services, has proudly announced that its Series 7, 8, and 9 charger models have...

Continue Reading